Skip Navigation
  Search Menu
Find an Expert

 

Stephanie Louise Gaillard, M.D., Ph.D.

Photo of Dr. Stephanie Louise Gaillard, M.D., Ph.D.

Assistant Professor of Oncology

Languages: English, French

Expertise: Cervical Cancer, Chemotherapy, Endometrial Cancer, Immunotherapy, Ovarian Cancer, Targeted/Biologic Therapy

Background

Stéphanie Gaillard is a medical oncologist who specializes in the treatment of gynecologic malignancies. She recently joined the faculty of the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and is their Director of Gynecologic Cancer Trials. Dr. Gaillard earned her medical degree and doctoral degree in cancer biology from Duke University. Following medical school, she underwent residency training in Internal Medicine and fellowship training in Medical Oncology at the Johns Hopkins School of Medicine. She is board certified in Medical Oncology and Internal Medicine. Dr. Gaillard’s research focuses on the development of clinical trials aimed at improving outcomes by incorporating promising new biologic, targeted, and immune therapies into standard treatment regimens. Her translational research program focuses on understanding the immune environment associated with gynecologic cancers and mechanisms of resistance to current therapies.

...read more

Titles

  • Assistant Professor of Oncology
  • Assistant Professor of Gynecology and Obstetrics

Education

Degrees

  • MD, Duke University School of Medicine (2006)

Residencies

  • Johns Hopkins University School of Medicine / Internal Medicine (2009)

Fellowships

  • Johns Hopkins University School of Medicine / Hematology and Oncology (2012)

Board Certifications

  • American Board of Internal Medicine / Internal Medicine (2009)
  • American Board of Internal Medicine / Medical Oncology (2011)

Research & Publications

Selected Publications

Yu Y, Suryo Rahmanto Y, Lee MH, Wu PH, Phillip JM, Huang CH, Vitolo MI, Gaillard S, Martin SS, Wirtz D, Shih IM, Wang TL. Inhibition of ovarian tumor cell invasiveness by targeting SYK in the tyrosine kinase signaling pathway. Oncogene. 2018 Apr 11. PMID: 29643476.

Fader AN, Bergstrom J, Jernigan A, Tanner EJ 3rd, Roche KL, Stone RL, Levinson KL, Ricci S, Wethingon S, Wang TL, Shih IM, Yang B, Zhang G, Armstrong DK, Gaillard S, Michener C, DeBernardo R, Rose PG. Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival? Gynecol Oncol. 2017 Oct;147(1):85-91. PMID: 28768570

Machado KK and Gaillard SL. Emerging therapies in the management of High-Grade Serous Ovarian Carcinoma: a Focus on Parp Inhibitors. 2017 Sep; 6:3.

Gaillard SL, Secord AA, Monk B. The role of immune checkpoint inhibition in the treatment of ovarian cancer. Gynecol Oncol Res Pract. 2016 Nov 24; 3:11. PMID: 27904752

Yu Y, Gaillard S, Phillip JM, Huang T, Pinto SM, Zhang Z, Pandey A, Wirtz D, Wang T, Shih I. Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules. Cancer Cell. 2015 Jul 13:28(1):82-96. PMID: 26096845

Cobb LP, Gaillard S, Wang Y, Shih I, Alvarez Secord A. Adenocarcinoma of Mullerian Origin: Review of Pathogenesis, Molecular Biology, and Emerging Treatment Paradigms. Gynecologic Oncology Research and Practice. 2015 May 12;2:1. PMID: 27231561

Is this you? Edit Profile